Obinutuzumab for B-cell malignancies

Expert Opinion on Biological Therapy

Volumn 14, Issue 8, 2014, Pages 1197-1205

  Owen, Carolyn J ^a   Stewart, Douglas A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antibody; CD20; Chronic lymphocytic leukaemia; Non Hodgkin lymphoma

Indexed keywords

OBINUTUZUMAB; RITUXIMAB; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

B CELL LYMPHOMA; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT OUTCOME; ANIMAL; B LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; METABOLISM; PATHOLOGY; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; NEOPLASM RECURRENCE, LOCAL;

EID: 84904015461     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.922535     Document Type: Review

References (55)

1. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44(16):3823-37 (Pubitemid 47332625)
2. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51(6):983-94
3. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-Term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116(12):2040-5
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23 (Pubitemid 40223656)
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32 (Pubitemid 41742196)
7. Hainsworth JD, Litchy S, Barton JH, et al. Single-Agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21(9):1746-51 (Pubitemid 46638587)
8. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101(3):1045-52 (Pubitemid 36139378)
9. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172(5):3280-8 (Pubitemid 38263720)
10. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103(7):2738-43 (Pubitemid 38393032)
11. Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008;14(20):6697-703
12. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complementprotecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance. J Clin Oncol 2003;21(8):1466-71 (Pubitemid 46594097)
13. Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011;10(1):178-85
14. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186(6):3762-9
15. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171(3):1581-7 (Pubitemid 36900094)
16. Cittera E, Leidi M, Buracchi C, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol 2007;178(10):6616-23 (Pubitemid 46717446)
17. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199(12):1659-69 (Pubitemid 38821999)
18. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011;118(2):358-67
19. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101-10
20. Bologna L, Gotti E, Da Roit F, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013;190(1):231-9
21. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115(22):4393-402
22. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actindependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117(17):4519-29
23. Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013;122(20):3482-91
24. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119(8):2143-59
25. Jak M, van Bochove GG, Reits EA, et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 monoclonal antibody GA101. Blood 2011;118(19):5178-88
26. Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013;12(10):2031-42
27. Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12(3):343-51
28. Reslan L, Dalle S, Herveau S, et al. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: Comparison of rituximab and obinutuzumab. Leuk Lymphoma 2014;55(1):188-90
29. Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012;119(15):3523-33
30. Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011;118(9):2530-40
31. Vaughan AT, Iriyama C, Beers SA, et al. Inhibitory FcgammaRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 2014;123(5):669-77
32. Morschhauser F, Salles G, Cartron G, et al. Dose selection for Phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101)-A rational approach. European Hematology Association Annual Congress. Haematologica 2011;96(s2):0935a
33. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012;119(22):5118-25
34. Brown JR, O'Brien S, Kingsley CD, et al. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase Ib Galton trial (GAO4779g). Blood (ASH Annual Abstracts) 2013;122:523a
35. Cartron G, Morshhauser F, Thieblemont C, et al. Results from a Phase II study of obinutuzumab (GA101) monotherapy in relapsed/ refractory chronic lymphocytic leukemia (CLL). European Hematology Association Annual Congress. Haematologica 2011;96(s2):0101a
36. Cartron G, Morshhauser F, Thieblemont C, et al. Results from a Phase II study of obinutuzumab (GA101) monotherapy in relapsed/ refractory chronic lymphocytic leukemia (CLL). European Hematology Association Annual Congress. Haematologica 2011;96(s2):0101a 36. Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: Results of the CLL11 (BO21004) safety run-in. Leukemia 2013;27(5):1172-4
37. Bottcher S, Ritgen M, Fisher K, et al. Minimal residual disease quantification is an independent predictor of progressionfree and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30:980-8
38. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012;119(22):5126-32
39. Salles GA, Morschhauser F, Solal-Celigny P, et al. Obinutuzumab (GA101) in patients with relapsed/ refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2920-6
40. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: Results of the GAUDI study (BO21000). Blood 2013;122(7):1137-43
41. Davies A, Radford J, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: Final data from the maintenance phase of the phase 1b GAUDI study (B021000). Blood (ASH Annual Abstracts) 2013;122:1814a
42. Sehn LH, Goy A, Offner FC, et al. Randomized Phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Preliminary analysis of the GAUSS study. Blood (ASH Annual Meeting Abstracts) 2011;118(22):269a
43. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/ refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2912-19
44. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32-42
45. Macias-Perez IM, Flinn IW. GS-1101: A delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2013;8(1):22-7
46. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202-8
47. Herting F, Bader S, Umana P, Klein C. Enhanced activity of GA101, a novel Type II, glycoengineered CD20 antibody, in combination wtih bendamustine or fludarabine, and with the Bcl-2 family inhibitors ABT-737 or ABT-263. Blood (ASH Annual Meeting Abstracts) 2010;116(21):3915a
48. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33 (Pubitemid 28363048)
49. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 1999;62(2):76-82 (Pubitemid 29071265)
50. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19(8):2153-64 (Pubitemid 32366969)
51. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19(8):2165-70 (Pubitemid 32366970)
52. O'Brien S, Wierda WG, Federl S, et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia. Blood (ASH Annual Abstracts) 2005;106:2117a
53. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999;94(7):2217-24 (Pubitemid 29467667)
54. Gaston RS, Deierhoi MH, Patterson T, et al. OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kidney Int 1991;39(1):141-8
55. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokinerelease syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996;98(12):2819-26 (Pubitemid 26427411).